Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “Two similar examples of process-driven losses from the fourth quarter of 2025 were the declines we experienced in shares of XOMA Royalty Corp (XOMA) and Clearpoint Neuro (CLPT). We consider both of these companies to be platform companies, with XOMA operating in the biotech royalty space. XOMA is leveraged to a broad portfolio of partnered products that should drive long-term growth. The stock had been a winner for Minot Light due to excitement around potential near-term data read-outs and approvals of partner products. Unfortunately, disappointing data and regulatory outcomes during the fourth quarter caused the stock to correct. Though disappointing in the near term, we continue to own XOMA and believe it has a bright future ahead with many more shots on goal. BSD Analysis: XOMA is a royalty company monetizing biotech innovation without funding R&D itself. Cash flows depend on partners' success rather than internal execution. Revenue is lumpy, but margins are extremely high. Investors struggle with valuation due to complexity. The portfolio approach reduces binary risk relative to single-asset biotechs. Optionality exists if pipeline assets mature. Capital allocation discipline is key. This is biotech exposure without biotech burn. Patience is the currency.” | BULL | Q4 2025 Jan 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
